Evidence map›Paper›PMID 36639740›Full record

ArticleBMC infectious diseases2023

A case of novel, rapidly-growing Mycolicibacter kumamotonensis infection in a patient with severe pulmonary disease treated in New York City.

Maxwell D Weidmann, Yuexiu Wu, Fann Wu, Dhrupa D Hapani, Daniel A Green, Justin G Aaron, Gregory J Berry

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. PulmonaryJournal of community hospital internal medicine perspectives · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maxwell D Weidmann *Department of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA.
Yuexiu Wu *Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Fann WuDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA.
Dhrupa D HapaniDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA.
Daniel A GreenDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA.
Justin G AaronDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Gregory J BerryDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA. gb2755@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-0767-6826
Columbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMycolicibacter kumamotonensis is a slowly growing, non-chromogenic non-tuberculous mycobacteria (NTM) that was initially distinguished from the M. terrae complex in 2006. Since then it has been rarely reported as the cause of pulmonary and soft-tissue infections in both immunocompromised and immunocompetent patients. CASE PRESENTATION: We present a case of severe pulmonary disease due to Mycolicibacter kumamotonensis in a 57-year-old male who was immunocompetent at time of diagnosis, with a history of interstitial lung disease and a prior diagnosis of tuberculosis (TB). After initial treatment for TB in 2017, his condition stabilized until a recurrence in September 2021, leading to an evaluation for lung transplant in the setting of pulmonary fibrosis and emphysema which led to the identification of Mycolicibacter kumamotonensis. A lung transplant was completed, and the patient was successfully treated with a combination of Ethambutol, Azithromycin, and Rifabutin.

conclusionsThis represents the first case reported of M. kumamotonensis in a patient undergoing lung transplant, and the first case with rapid culture growth during identification of the organism (4 days). This report highlights the need for consideration of M. kumamotonensis as a pathogen in humans, with the potential for rapid growth in liquid media, and the importance of early identification to inform empiric therapy.

Indexed as

Lung DiseasesMycobacterium Infections, NontuberculousTuberculosisHumansMaleMiddle AgedMycobacteriaceaeNew York CityNontuberculous MycobacteriaCase reportKumamotonensisNon-tuberculous mycobacteriaPost-transplantRapid growth

Identifiers

PMID36639740
PMCPMC9840340
OpenAlexW4316036610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.